Skip to main content
Top
Published in: Journal of Translational Medicine 1/2011

Open Access 01-12-2011 | Research

Cytotoxic T lymphocyte responses against melanocytes and melanoma

Authors: Gwendolen Y Chang, Holbrook E Kohrt, Tor B Stuge, Erich J Schwartz, Jeffrey S Weber, Peter P Lee

Published in: Journal of Translational Medicine | Issue 1/2011

Login to get access

Abstract

Background

Vitiligo is a common toxicity associated with immunotherapy for melanoma. Cytotoxic T lymphocytes (CTLs) against melanoma commonly target melanoma-associated antigens (MAAs) which are also expressed by melanocytes. To uncouple vitiligo from melanoma destruction, it is important to understand if CTLs can respond against melanoma and melanocytes at different levels.

Methods

To understand the dichotomous role of MAA-specific CTL, we characterized the functional reactivities of established CTL clones directed to MAAs against melanoma and melanocyte cell lines.

Results

CTL clones generated from melanoma patients were capable of eliciting MHC-restricted, MAA-specific lysis against melanocyte cell lines as well as melanoma cells. Among the tested HLA-A*0201-restricted CTL clones, melanocytes evoked equal to slightly higher degranulation and cytolytic responses as compared to melanoma cells. Moreover, MAA-specific T cells from vaccinated patients responded directly ex vivo to melanoma and melanocytes. Melanoma cells express slightly higher levels of MART-1 and gp100 than melanocytes as measured by quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) and immunohistochemistry.

Conclusions

Our data suggest that CTLs respond to melanoma and melanocytes equally in vitro and directly ex vivo.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010, 363: 711-723. 10.1056/NEJMoa1003466.PubMedCentralCrossRefPubMed Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010, 363: 711-723. 10.1056/NEJMoa1003466.PubMedCentralCrossRefPubMed
2.
go back to reference Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, Wunderlich J, Restifo NP, Thomasian A, Downey SG, Smith FO, Klapper J, Morton K, Laurencot C, White DE, Rosenberg SA: Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008, 26: 5233-5239. 10.1200/JCO.2008.16.5449.PubMedCentralCrossRefPubMed Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, Wunderlich J, Restifo NP, Thomasian A, Downey SG, Smith FO, Klapper J, Morton K, Laurencot C, White DE, Rosenberg SA: Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008, 26: 5233-5239. 10.1200/JCO.2008.16.5449.PubMedCentralCrossRefPubMed
3.
go back to reference Yee C, Thompson JA, Roche P, Byrd DR, Lee PP, Piepkorn M, Kenyon K, Davis MM, Riddell SR, Greenberg PD: Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. J Exp Med. 2000, 192: 1637-1644. 10.1084/jem.192.11.1637.PubMedCentralCrossRefPubMed Yee C, Thompson JA, Roche P, Byrd DR, Lee PP, Piepkorn M, Kenyon K, Davis MM, Riddell SR, Greenberg PD: Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. J Exp Med. 2000, 192: 1637-1644. 10.1084/jem.192.11.1637.PubMedCentralCrossRefPubMed
4.
go back to reference Garbelli S, Mantovani S, Palermo B, Giachino C: Melanocyte-specific, cytotoxic T cell responses in vitiligo: the effective variant of melanoma immunity?. Pigment Cell Res. 2005, 18: 234-242. 10.1111/j.1600-0749.2005.00244.x.CrossRefPubMed Garbelli S, Mantovani S, Palermo B, Giachino C: Melanocyte-specific, cytotoxic T cell responses in vitiligo: the effective variant of melanoma immunity?. Pigment Cell Res. 2005, 18: 234-242. 10.1111/j.1600-0749.2005.00244.x.CrossRefPubMed
5.
go back to reference Wankowicz-Kalinska A, Le Poole C, van den Wijngaard R, Storkus WJ, Das PK: Melanocyte-specific immune response in melanoma and vitiligo: two faces of the same coin?. Pigment Cell Res. 2003, 16: 254-260. 10.1034/j.1600-0749.2003.00038.x.CrossRefPubMed Wankowicz-Kalinska A, Le Poole C, van den Wijngaard R, Storkus WJ, Das PK: Melanocyte-specific immune response in melanoma and vitiligo: two faces of the same coin?. Pigment Cell Res. 2003, 16: 254-260. 10.1034/j.1600-0749.2003.00038.x.CrossRefPubMed
6.
go back to reference Palmer DC, Chan CC, Gattinoni L, Wrzesinski C, Paulos CM, Hinrichs CS, Powell DJ, Klebanoff CA, Finkelstein SE, Fariss RN, Yu Z, Nussenblatt RB, Rosenberg SA, Restifo NP: Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. Proc Natl Acad Sci USA. 2008, 105: 8061-8066. 10.1073/pnas.0710929105.PubMedCentralCrossRefPubMed Palmer DC, Chan CC, Gattinoni L, Wrzesinski C, Paulos CM, Hinrichs CS, Powell DJ, Klebanoff CA, Finkelstein SE, Fariss RN, Yu Z, Nussenblatt RB, Rosenberg SA, Restifo NP: Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. Proc Natl Acad Sci USA. 2008, 105: 8061-8066. 10.1073/pnas.0710929105.PubMedCentralCrossRefPubMed
7.
go back to reference Bouwhuis MG, Ten Hagen TL, Suciu S, Eggermont AM: Autoimmunity and treatment outcome in melanoma. Curr Opin Oncol. 2011, 23: 170-176. 10.1097/CCO.0b013e328341edff.CrossRefPubMed Bouwhuis MG, Ten Hagen TL, Suciu S, Eggermont AM: Autoimmunity and treatment outcome in melanoma. Curr Opin Oncol. 2011, 23: 170-176. 10.1097/CCO.0b013e328341edff.CrossRefPubMed
8.
go back to reference Rosenberg SA, Kawakami Y, Robbins PF, Wang R: Identification of the genes encoding cancer antigens: implications for cancer immunotherapy. Adv Cancer Res. 1996, 70: 145-177.CrossRefPubMed Rosenberg SA, Kawakami Y, Robbins PF, Wang R: Identification of the genes encoding cancer antigens: implications for cancer immunotherapy. Adv Cancer Res. 1996, 70: 145-177.CrossRefPubMed
9.
go back to reference Boon T: Tumor antigens recognized by cytolytic T lymphocytes: present perspectives for specific immunotherapy. Int J Cancer. 1993, 54: 177-180. 10.1002/ijc.2910540202.CrossRefPubMed Boon T: Tumor antigens recognized by cytolytic T lymphocytes: present perspectives for specific immunotherapy. Int J Cancer. 1993, 54: 177-180. 10.1002/ijc.2910540202.CrossRefPubMed
10.
go back to reference Kawakami Y, Robbins PF, Wang RF, Parkhurst M, Kang X, Rosenberg SA: The use of melanosomal proteins in the immunotherapy of melanoma. J Immunother. 1998, 21: 237-246. 10.1097/00002371-199807000-00001.CrossRefPubMed Kawakami Y, Robbins PF, Wang RF, Parkhurst M, Kang X, Rosenberg SA: The use of melanosomal proteins in the immunotherapy of melanoma. J Immunother. 1998, 21: 237-246. 10.1097/00002371-199807000-00001.CrossRefPubMed
11.
go back to reference Okamoto T, Irie RF, Fujii S, Huang SK, Nizze AJ, Morton DL, Hoon DS: Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy. J Invest Dermatol. 1998, 111: 1034-1039. 10.1046/j.1523-1747.1998.00411.x.CrossRefPubMed Okamoto T, Irie RF, Fujii S, Huang SK, Nizze AJ, Morton DL, Hoon DS: Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy. J Invest Dermatol. 1998, 111: 1034-1039. 10.1046/j.1523-1747.1998.00411.x.CrossRefPubMed
12.
go back to reference Guevara-Patino JA, Turk MJ, Wolchok JD, Houghton AN: Immunity to cancer through immune recognition of altered self: studies with melanoma. Adv Cancer Res. 2003, 90: 157-177.CrossRefPubMed Guevara-Patino JA, Turk MJ, Wolchok JD, Houghton AN: Immunity to cancer through immune recognition of altered self: studies with melanoma. Adv Cancer Res. 2003, 90: 157-177.CrossRefPubMed
13.
go back to reference Morgan DJ, Kreuwel HT, Fleck S, Levitsky HI, Pardoll DM, Sherman LA: Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J Immunol. 1998, 160: 643-651.PubMed Morgan DJ, Kreuwel HT, Fleck S, Levitsky HI, Pardoll DM, Sherman LA: Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J Immunol. 1998, 160: 643-651.PubMed
14.
go back to reference Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, Roederer M, Koup RA: Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods. 2003, 281: 65-78. 10.1016/S0022-1759(03)00265-5.CrossRefPubMed Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, Roederer M, Koup RA: Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods. 2003, 281: 65-78. 10.1016/S0022-1759(03)00265-5.CrossRefPubMed
15.
go back to reference Kohrt HE, Shu CT, Stuge TB, Holmes SP, Weber J, Lee PP: Rapid assessment of recognition efficiency and functional capacity of antigen-specific T-cell responses. J Immunother. 2005, 28: 297-305. 10.1097/01.cji.0000162780.96310.e4.CrossRefPubMed Kohrt HE, Shu CT, Stuge TB, Holmes SP, Weber J, Lee PP: Rapid assessment of recognition efficiency and functional capacity of antigen-specific T-cell responses. J Immunother. 2005, 28: 297-305. 10.1097/01.cji.0000162780.96310.e4.CrossRefPubMed
16.
go back to reference Rubio V, Stuge TB, Singh N, Betts MR, Weber JS, Roederer M, Lee PP: Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med. 2003, 9: 1377-1382. 10.1038/nm942.CrossRefPubMed Rubio V, Stuge TB, Singh N, Betts MR, Weber JS, Roederer M, Lee PP: Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med. 2003, 9: 1377-1382. 10.1038/nm942.CrossRefPubMed
17.
go back to reference Stuge TB, Holmes SP, Saharan S, Tuettenberg A, Roederer M, Weber JS, Lee PP: Diversity and recognition efficiency of T cell responses to cancer. PLoS Med. 2004, 1: e28-10.1371/journal.pmed.0010028.PubMedCentralCrossRefPubMed Stuge TB, Holmes SP, Saharan S, Tuettenberg A, Roederer M, Weber JS, Lee PP: Diversity and recognition efficiency of T cell responses to cancer. PLoS Med. 2004, 1: e28-10.1371/journal.pmed.0010028.PubMedCentralCrossRefPubMed
18.
go back to reference Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987, 162: 156-159.CrossRefPubMed Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987, 162: 156-159.CrossRefPubMed
19.
go back to reference Jungbluth AA, Iversen K, Coplan K, Williamson B, Chen YT, Stockert E, Old LJ, Busam KJ: Expression of melanocyte-associated markers gp-100 and Melan-A/MART-1 in angiomyolipomas. An immunohistochemical and rt-PCR analysis. Virchows Arch. 1999, 434: 429-435. 10.1007/s004280050362.CrossRefPubMed Jungbluth AA, Iversen K, Coplan K, Williamson B, Chen YT, Stockert E, Old LJ, Busam KJ: Expression of melanocyte-associated markers gp-100 and Melan-A/MART-1 in angiomyolipomas. An immunohistochemical and rt-PCR analysis. Virchows Arch. 1999, 434: 429-435. 10.1007/s004280050362.CrossRefPubMed
20.
go back to reference Carrabba MG, Castelli C, Maeurer MJ, Squarcina P, Cova A, Pilla L, Renkvist N, Parmiani G, Rivoltini L: Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues. Cancer Res. 2003, 63: 1560-1567.PubMed Carrabba MG, Castelli C, Maeurer MJ, Squarcina P, Cova A, Pilla L, Renkvist N, Parmiani G, Rivoltini L: Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues. Cancer Res. 2003, 63: 1560-1567.PubMed
21.
go back to reference Yee C, Savage PA, Lee PP, Davis MM, Greenberg PD: Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J Immunol. 1999, 162: 2227-2234.PubMed Yee C, Savage PA, Lee PP, Davis MM, Greenberg PD: Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J Immunol. 1999, 162: 2227-2234.PubMed
22.
go back to reference Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, Panagiotou P, Polyzos A, Papadopoulos O, Stratigos A: Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006, 354: 709-718. 10.1056/NEJMoa053007.CrossRefPubMed Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, Panagiotou P, Polyzos A, Papadopoulos O, Stratigos A: Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006, 354: 709-718. 10.1056/NEJMoa053007.CrossRefPubMed
23.
go back to reference Nordlund JJ, Kirkwood JM, Forget BM, Milton G, Albert DM, Lerner AB: Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol. 1983, 9: 689-696. 10.1016/S0190-9622(83)70182-9.CrossRefPubMed Nordlund JJ, Kirkwood JM, Forget BM, Milton G, Albert DM, Lerner AB: Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol. 1983, 9: 689-696. 10.1016/S0190-9622(83)70182-9.CrossRefPubMed
24.
go back to reference Bystryn JC, Rigel D, Friedman RJ, Kopf A: Prognostic significance of hypopigmentation in malignant melanoma. Arch Dermatol. 1987, 123: 1053-1055. 10.1001/archderm.123.8.1053.CrossRefPubMed Bystryn JC, Rigel D, Friedman RJ, Kopf A: Prognostic significance of hypopigmentation in malignant melanoma. Arch Dermatol. 1987, 123: 1053-1055. 10.1001/archderm.123.8.1053.CrossRefPubMed
25.
go back to reference Boasberg PD, Hoon DS, Piro LD, Martin MA, Fujimoto A, Kristedja TS, Bhachu S, Ye X, Deck RR, O'Day SJ: Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma. J Invest Dermatol. 2006, 126: 2658-2663. 10.1038/sj.jid.5700545.CrossRefPubMed Boasberg PD, Hoon DS, Piro LD, Martin MA, Fujimoto A, Kristedja TS, Bhachu S, Ye X, Deck RR, O'Day SJ: Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma. J Invest Dermatol. 2006, 126: 2658-2663. 10.1038/sj.jid.5700545.CrossRefPubMed
26.
go back to reference Le Gal FA, Avril MF, Bosq J, Lefebvre P, Deschemin JC, Andrieu M, Dore MX, Guillet JG: Direct evidence to support the role of antigen-specific CD8(+) T cells in melanoma-associated vitiligo. J Invest Dermatol. 2001, 117: 1464-1470. 10.1046/j.0022-202x.2001.01605.x.CrossRefPubMed Le Gal FA, Avril MF, Bosq J, Lefebvre P, Deschemin JC, Andrieu M, Dore MX, Guillet JG: Direct evidence to support the role of antigen-specific CD8(+) T cells in melanoma-associated vitiligo. J Invest Dermatol. 2001, 117: 1464-1470. 10.1046/j.0022-202x.2001.01605.x.CrossRefPubMed
27.
go back to reference Rubio-Godoy V, Dutoit V, Rimoldi D, Lienard D, Lejeune F, Speiser D, Guillaume P, Cerottini JC, Romero P, Valmori D: Discrepancy between ELISPOT IFN-gamma secretion and binding of A2/peptide multimers to TCR reveals interclonal dissociation of CTL effector function from TCR-peptide/MHC complexes half-life. Proc Natl Acad Sci USA. 2001, 98: 10302-10307. 10.1073/pnas.181348898.PubMedCentralCrossRefPubMed Rubio-Godoy V, Dutoit V, Rimoldi D, Lienard D, Lejeune F, Speiser D, Guillaume P, Cerottini JC, Romero P, Valmori D: Discrepancy between ELISPOT IFN-gamma secretion and binding of A2/peptide multimers to TCR reveals interclonal dissociation of CTL effector function from TCR-peptide/MHC complexes half-life. Proc Natl Acad Sci USA. 2001, 98: 10302-10307. 10.1073/pnas.181348898.PubMedCentralCrossRefPubMed
28.
go back to reference Schallreuter KU, Levenig C, Berger J: Vitiligo and cutaneous melanoma. A case study. Dermatologica. 1991, 183: 239-245. 10.1159/000247693.CrossRefPubMed Schallreuter KU, Levenig C, Berger J: Vitiligo and cutaneous melanoma. A case study. Dermatologica. 1991, 183: 239-245. 10.1159/000247693.CrossRefPubMed
29.
go back to reference Steitz J, Bruck J, Lenz J, Buchs S, Tuting T: Peripheral CD8+ T cell tolerance against melanocytic self-antigens in the skin is regulated in two steps by CD4+ T cells and local inflammation: implications for the pathophysiology of vitiligo. J Invest Dermatol. 2005, 124: 144-150. 10.1111/j.0022-202X.2004.23538.x.CrossRefPubMed Steitz J, Bruck J, Lenz J, Buchs S, Tuting T: Peripheral CD8+ T cell tolerance against melanocytic self-antigens in the skin is regulated in two steps by CD4+ T cells and local inflammation: implications for the pathophysiology of vitiligo. J Invest Dermatol. 2005, 124: 144-150. 10.1111/j.0022-202X.2004.23538.x.CrossRefPubMed
30.
go back to reference Jacobs JF, Aarntzen EH, Sibelt LA, Blokx WA, Boullart AC, Gerritsen MJ, Hoogerbrugge PM, Figdor CG, Adema GJ, Punt CJ, de Vries IJ: Vaccine-specific local T cell reactivity in immunotherapy-associated vitiligo in melanoma patients. Cancer Immunol Immunother. 2009, 58: 145-151. 10.1007/s00262-008-0506-5.CrossRefPubMed Jacobs JF, Aarntzen EH, Sibelt LA, Blokx WA, Boullart AC, Gerritsen MJ, Hoogerbrugge PM, Figdor CG, Adema GJ, Punt CJ, de Vries IJ: Vaccine-specific local T cell reactivity in immunotherapy-associated vitiligo in melanoma patients. Cancer Immunol Immunother. 2009, 58: 145-151. 10.1007/s00262-008-0506-5.CrossRefPubMed
31.
go back to reference Rivoltini L, Barracchini KC, Viggiano V, Kawakami Y, Smith A, Mixon A, Restifo NP, Topalian SL, Simonis TB, Rosenberg SA, Marincola FM: Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. Cancer Res. 1995, 55: 3149-3157.PubMedCentralPubMed Rivoltini L, Barracchini KC, Viggiano V, Kawakami Y, Smith A, Mixon A, Restifo NP, Topalian SL, Simonis TB, Rosenberg SA, Marincola FM: Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. Cancer Res. 1995, 55: 3149-3157.PubMedCentralPubMed
32.
go back to reference Lethe B, van der Bruggen P, Brasseur F, Boon T: MAGE-1 expression threshold for the lysis of melanoma cell lines by a specific cytotoxic T lymphocyte. Melanoma Res. 1997, 7 (Suppl 2): S83-88.PubMed Lethe B, van der Bruggen P, Brasseur F, Boon T: MAGE-1 expression threshold for the lysis of melanoma cell lines by a specific cytotoxic T lymphocyte. Melanoma Res. 1997, 7 (Suppl 2): S83-88.PubMed
33.
go back to reference Riker AI, Kammula US, Panelli MC, Wang E, Ohnmacht GA, Steinberg SM, Rosenberg SA, Marincola FM: Threshold levels of gene expression of the melanoma antigen gp100 correlate with tumor cell recognition by cytotoxic T lymphocytes. Int J Cancer. 2000, 86: 818-826. 10.1002/(SICI)1097-0215(20000615)86:6<818::AID-IJC10>3.0.CO;2-W.CrossRefPubMed Riker AI, Kammula US, Panelli MC, Wang E, Ohnmacht GA, Steinberg SM, Rosenberg SA, Marincola FM: Threshold levels of gene expression of the melanoma antigen gp100 correlate with tumor cell recognition by cytotoxic T lymphocytes. Int J Cancer. 2000, 86: 818-826. 10.1002/(SICI)1097-0215(20000615)86:6<818::AID-IJC10>3.0.CO;2-W.CrossRefPubMed
34.
go back to reference Barrow C, Browning J, MacGregor D, Davis ID, Sturrock S, Jungbluth AA, Cebon J: Tumor antigen expression in melanoma varies according to antigen and stage. Clin Cancer Res. 2006, 12: 764-771. 10.1158/1078-0432.CCR-05-1544.CrossRefPubMed Barrow C, Browning J, MacGregor D, Davis ID, Sturrock S, Jungbluth AA, Cebon J: Tumor antigen expression in melanoma varies according to antigen and stage. Clin Cancer Res. 2006, 12: 764-771. 10.1158/1078-0432.CCR-05-1544.CrossRefPubMed
35.
go back to reference Murer K, Urosevic M, Willers J, Selvam P, Laine E, Burg G, Dummer R: Expression of Melan-A/MART-1 in primary melanoma cell cultures has prognostic implication in metastatic melanoma patients. Melanoma Res. 2004, 14: 257-262. 10.1097/01.cmr.0000136713.21029.56.CrossRefPubMed Murer K, Urosevic M, Willers J, Selvam P, Laine E, Burg G, Dummer R: Expression of Melan-A/MART-1 in primary melanoma cell cultures has prognostic implication in metastatic melanoma patients. Melanoma Res. 2004, 14: 257-262. 10.1097/01.cmr.0000136713.21029.56.CrossRefPubMed
36.
go back to reference Urosevic M, Braun B, Willers J, Burg G, Dummer R: Expression of melanoma-associated antigens in melanoma cell cultures. Exp Dermatol. 2005, 14: 491-497. 10.1111/j.0906-6705.2005.00305.x.CrossRefPubMed Urosevic M, Braun B, Willers J, Burg G, Dummer R: Expression of melanoma-associated antigens in melanoma cell cultures. Exp Dermatol. 2005, 14: 491-497. 10.1111/j.0906-6705.2005.00305.x.CrossRefPubMed
37.
go back to reference Khong HT, Wang QJ, Rosenberg SA: Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression. J Immunother. 2004, 27: 184-190. 10.1097/00002371-200405000-00002.PubMedCentralCrossRefPubMed Khong HT, Wang QJ, Rosenberg SA: Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression. J Immunother. 2004, 27: 184-190. 10.1097/00002371-200405000-00002.PubMedCentralCrossRefPubMed
38.
go back to reference Durda PJ, Dunn IS, Rose LB, Butera D, Benson EM, Pandolfi F, Kurnick JT: Induction of "antigen silencing" in melanomas by oncostatin M: down-modulation of melanocyte antigen expression. Mol Cancer Res. 2003, 1: 411-419.PubMed Durda PJ, Dunn IS, Rose LB, Butera D, Benson EM, Pandolfi F, Kurnick JT: Induction of "antigen silencing" in melanomas by oncostatin M: down-modulation of melanocyte antigen expression. Mol Cancer Res. 2003, 1: 411-419.PubMed
39.
go back to reference Kurnick JT, Ramirez-Montagut T, Boyle LA, Andrews DM, Pandolfi F, Durda PJ, Butera D, Dunn IS, Benson EM, Gobin SJ, van den Elsen PJ: A novel autocrine pathway of tumor escape from immune recognition: melanoma cell lines produce a soluble protein that diminishes expression of the gene encoding the melanocyte lineage melan-A/MART-1 antigen through down-modulation of its promoter. J Immunol. 2001, 167: 1204-1211.CrossRefPubMed Kurnick JT, Ramirez-Montagut T, Boyle LA, Andrews DM, Pandolfi F, Durda PJ, Butera D, Dunn IS, Benson EM, Gobin SJ, van den Elsen PJ: A novel autocrine pathway of tumor escape from immune recognition: melanoma cell lines produce a soluble protein that diminishes expression of the gene encoding the melanocyte lineage melan-A/MART-1 antigen through down-modulation of its promoter. J Immunol. 2001, 167: 1204-1211.CrossRefPubMed
40.
go back to reference Maeurer MJ, Gollin SM, Storkus WJ, Swaney W, Karbach J, Martin D, Castelli C, Salter R, Knuth A, Lotze MT: Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6. Clin Cancer Res. 1996, 2: 641-652.PubMed Maeurer MJ, Gollin SM, Storkus WJ, Swaney W, Karbach J, Martin D, Castelli C, Salter R, Knuth A, Lotze MT: Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6. Clin Cancer Res. 1996, 2: 641-652.PubMed
Metadata
Title
Cytotoxic T lymphocyte responses against melanocytes and melanoma
Authors
Gwendolen Y Chang
Holbrook E Kohrt
Tor B Stuge
Erich J Schwartz
Jeffrey S Weber
Peter P Lee
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2011
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-9-122

Other articles of this Issue 1/2011

Journal of Translational Medicine 1/2011 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.